Switch theme
Sign up to access all valuation multiples
Inhalation Sciences Sweden AB develops and commercializes patented lab instrument for inhalation research. Its products include PreciseInhale an advanced laboratory system used to measure inhaled particles and their effect on lungs, and LaminarPace tool for drying small amounts of the drug substance.
2004
9
Last FY Revenue $1.1M
Last FY EBITDA -$0.4M
$0.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Inhalation Sciences SWE achieved revenue of $1.1M and an EBITDA of -$0.4M.
Inhalation Sciences SWE expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Inhalation Sciences SWE valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.1M | XXX | XXX | XXX |
| Gross Profit | XXX | $1.0M | XXX | XXX | XXX |
| Gross Margin | XXX | 92% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -36% | XXX | XXX | XXX |
| EBIT | XXX | -$0.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | -46% | XXX | XXX | XXX |
| Net Profit | XXX | -$0.5M | XXX | XXX | XXX |
| Net Margin | XXX | -47% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Inhalation Sciences SWE's stock price is SEK 0 (or $0).
Inhalation Sciences SWE has current market cap of SEK 8.3M (or $0.9M), and EV of SEK 5.4M (or $0.6M).
See Inhalation Sciences SWE trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $0.6M | $0.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Inhalation Sciences SWE has market cap of $0.9M and EV of $0.6M.
Inhalation Sciences SWE's trades at 0.5x EV/Revenue multiple, and -1.4x EV/EBITDA.
Equity research analysts estimate Inhalation Sciences SWE's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inhalation Sciences SWE's P/E ratio is not available.
See valuation multiples for Inhalation Sciences SWE and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $0.9M | XXX | $0.9M | XXX | XXX | XXX |
| EV (current) | $0.6M | XXX | $0.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInhalation Sciences SWE's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Inhalation Sciences SWE's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Inhalation Sciences SWE's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Inhalation Sciences SWE and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -36% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 98% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 137% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inhalation Sciences SWE acquired XXX companies to date.
Last acquisition by Inhalation Sciences SWE was XXXXXXXX, XXXXX XXXXX XXXXXX . Inhalation Sciences SWE acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Inhalation Sciences SWE founded? | Inhalation Sciences SWE was founded in 2004. |
| Where is Inhalation Sciences SWE headquartered? | Inhalation Sciences SWE is headquartered in Sweden. |
| How many employees does Inhalation Sciences SWE have? | As of today, Inhalation Sciences SWE has 9 employees. |
| Is Inhalation Sciences SWE publicy listed? | Yes, Inhalation Sciences SWE is a public company listed on SAT. |
| What is the stock symbol of Inhalation Sciences SWE? | Inhalation Sciences SWE trades under ISAB ticker. |
| When did Inhalation Sciences SWE go public? | Inhalation Sciences SWE went public in 2017. |
| Who are competitors of Inhalation Sciences SWE? | Similar companies to Inhalation Sciences SWE include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Inhalation Sciences SWE? | Inhalation Sciences SWE's current market cap is $0.9M |
| Is Inhalation Sciences SWE profitable? | Yes, Inhalation Sciences SWE is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
